The new patent covers the controlled release of drugs and other active compounds, including growth factors that can be incorporated in the wound dressing.
The patent entitled ‘Hydrogel Wound Dressing and Biomaterials Formed In Situ and Their Uses,’ provides additional coverage for Altrazeal including The Patent Term Adjustment granted by the USPTO, extends patent coverage on Altrazeal until January 2029.
Initially, the company has received US patent in 2007 that covers NanoFlex technology which is used to manufacture Altrazeal was due to expire in November 2022.
ULURU president and CEO Kerry Gray said this patent is the cornerstone of their wound care franchise, for both the current product portfolio and their extensive pipeline of development candidates.
"This intellectual property adds significant value to the Altrazeal asset due to the extension of patent coverage to 2029 and the subject matter covered," Gray said.